サンプル依頼リスト カート
  • English
  • Korean
デフォルト表紙
市場調査レポート
商品コード
1783994

肺腺がん治療の世界市場

Lung Adenocarcinoma Treatment

出版日
ページ情報
英文 291 Pages
納期
即日から翌営業日
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=148.26円
肺腺がん治療の世界市場
出版日: 2025年08月05日
発行: Global Industry Analysts, Inc.
ページ情報: 英文 291 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

肺腺がん治療の世界市場は2030年までに102億米ドルに達する見込み

2024年に59億米ドルと推定される肺腺がん治療の世界市場は、2024～2030年の分析期間においてCAGR 9.6%で成長し、2030年には102億米ドルに達すると予測されます。本レポートで分析したセグメントの1つである化学療法は、CAGR 7.7%を記録し、分析期間終了時には35億米ドルに達すると予測されます。標的療法分野の成長率は、分析期間でCAGR 11.4％と推定されます。

米国市場は16億米ドルと推定、中国はCAGR 12.8％で成長予測

米国の肺腺がん治療市場は、2024年に16億米ドルと推定されます。世界第2位の経済大国である中国は、2024年から2030年の分析期間においてCAGR 12.8%で推移し、2030年までに20億米ドルの市場規模に達すると予測されています。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ7.1%と8.3%と予測されています。欧州では、ドイツがCAGR約7.5%で成長すると予測されています。

世界の肺腺がん治療市場- 主要動向と促進要因まとめ

肺腺がんががん領域で際立つ理由とは？

非小細胞肺がん（NSCLC）のサブタイプである肺腺がんは、肺がん症例の40％近くを占め、肺がんの中で最も罹患率の高い疾患です。その罹患率の増加は、大気汚染や喫煙などの環境曝露や特定の集団における遺伝的素因に大きく関係しています。腫瘍学の領域でこの病気が際立っているのは、その複雑な分子プロファイルであり、これが標的治療の革新の波に拍車をかけています。EGFR変異からALKやROS1再配列に至るまで、発がんドライバーの同定は治療戦略を再定義し、製薬研究をより個別化されたバイオマーカー主導の治療レジメンへと押し進めています。従来の化学療法とは対照的に、これらの治療法はより少ない全身性副作用でより高い有効性を提供し、初期段階と進行段階の両方において患者ケアのパラダイムを変革しています。

新たな治療法は標準治療を再構築するか？

免疫療法や次世代標的治療の導入により、肺腺がんの治療状況は激変しています。ペムブロリズマブやニボルマブなどの免疫チェックポイント阻害剤は、特に初回治療として使用された場合、PD-L1高発現患者において有意な生存ベネフィットを示しました。一方、EGFRやその他の変異を標的とする第3世代のチロシンキナーゼ阻害薬（TKI）の登場は、特に耐性や転移性の症例において、治療成績をさらに改善しました。免疫剤と化学療法剤またはTKIを組み合わせた併用療法は、積極的に研究されており、臨床試験で有望視されています。さらに、二重特異性抗体、抗体薬物複合体（ADC）、mRNAベースのアプローチも開発中であり、腫瘍の進行や薬剤耐性に対する武器が拡大しています。これらの技術革新は、治療プロトコールにおける免疫学とゲノミクスの融合が進んでいることを反映しています。

診断のブレークスルーはどのように治療の精度を高めているのか？

診断の進歩は肺腺がんの治療経路を最適化する上で極めて重要な役割を果たしています。リキッドバイオプシー、次世代シークエンシング（NGS）、マルチプレックス分子プロファイリングは、臨床的意思決定において不可欠なツールとして台頭してきました。これらの技術は、最小限の生物学的材料から実用的な変異を検出することを可能にし、疾患の進行と治療効果をリアルタイムでモニタリングすることを可能にします。重要なことは、AI主導の診断プラットフォームの統合により、病理学的解析のスピードと精度が向上し、治療開始までの所要時間が改善されていることです。精密医療が標準となるにつれ、世界中の規制当局もこのシフトに同調し、コンパニオン診断薬の承認プロセスを合理化し、より広範なアクセスを確保しています。これらの動向は予後を改善するだけでなく、より適応的で費用対効果の高い治療モデルの導入を可能にします。

肺腺がん治療市場の成長の原動力は？

肺腺がん治療市場の成長は、技術革新、臨床診療の変化、患者層の進化に根ざしたいくつかの要因によって牽引されています。主な要因の1つは、分子診断と個別化治療アプローチの採用が増加していることであり、これによって医薬品開発と患者層別化が加速しています。もうひとつは、免疫チェックポイント阻害薬や標的治療の適応拡大で、対象となる患者層が大幅に広がっています。AIと機械学習の進歩は、創薬と臨床試験デザインを合理化し、新規治療の市場投入までの時間を短縮しています。さらに、肺がんに罹患しやすい世界の高齢者人口の増加や新興国における認知度の向上が、早期診断と治療率を押し上げています。また、製薬企業、バイオテクノロジー企業、学術機関の協力関係の高まりも、併用療法や次世代生物製剤の迅速な開発を促進しています。最後に、主要市場における償還支援とヘルスケア政策改革が、患者のプレミアム療法へのアクセスを向上させ、市場拡大をさらに後押ししています。

セグメント

治療（化学療法、標的療法、免疫療法、放射線療法、その他）、エンドユースチャネル（病院、専門クリニック、その他）

調査対象企業の例

  • AbbVie Inc.
  • Amgen Inc.
  • AstraZeneca PLC
  • BeiGene, Ltd.
  • BioNTech SE
  • Biotheus Inc.
  • Boehringer Ingelheim International GmbH
  • Bristol-Myers Squibb Company
  • CStone Pharmaceuticals
  • Daiichi Sankyo Company, Limited
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd
  • Genentech, Inc.（a member of the Roche Group）
  • GlaxoSmithKline plc
  • Johnson & Johnson Services, Inc.
  • Merck & Co., Inc.
  • Novartis AG
  • Pfizer Inc.
  • Sanofi S.A.
  • Takeda Pharmaceutical Company Limited

AI統合

当社は、有効な専門家コンテンツとAIツールにより、市場情報と競合情報を変革しています。

Global Industry Analystsは、LLMや業界固有のSLMを照会する一般的な規範に従う代わりに、ビデオ記録、ブログ、検索エンジン調査、膨大な量の企業、製品/サービス、市場データなど、世界中の専門家から収集したコンテンツのリポジトリを構築しました。

関税影響係数

Global Industry Analystsは、本社の国、製造拠点、輸出入（完成品とOEM）に基づく企業の競争力の変化を予測しています。この複雑で多面的な市場力学は、売上原価（COGS）の増加、収益性の低下、サプライチェーンの再構築など、ミクロおよびマクロの市場力学の中でも特に競合他社に影響を与える見込みです。

目次

第1章 調査手法

第2章 エグゼクティブサマリー

  • 市場概要
  • 主要企業
  • 市場動向と促進要因
  • 世界市場の見通し

第3章 市場分析

  • 米国
  • カナダ
  • 日本
  • 中国
  • 欧州
  • フランス
  • ドイツ
  • イタリア
  • 英国
  • スペイン
  • ロシア
  • その他欧州
  • アジア太平洋
  • オーストラリア
  • インド
  • 韓国
  • その他アジア太平洋地域
  • ラテンアメリカ
  • アルゼンチン
  • ブラジル
  • メキシコ
  • その他ラテンアメリカ
  • 中東
  • イラン
  • イスラエル
  • サウジアラビア
  • アラブ首長国連邦
  • その他中東
  • アフリカ

第4章 競合

目次
Product Code: MCP31928

Global Lung Adenocarcinoma Treatment Market to Reach US$10.2 Billion by 2030

The global market for Lung Adenocarcinoma Treatment estimated at US$5.9 Billion in the year 2024, is expected to reach US$10.2 Billion by 2030, growing at a CAGR of 9.6% over the analysis period 2024-2030. Chemotherapy, one of the segments analyzed in the report, is expected to record a 7.7% CAGR and reach US$3.5 Billion by the end of the analysis period. Growth in the Targeted Therapy segment is estimated at 11.4% CAGR over the analysis period.

The U.S. Market is Estimated at US$1.6 Billion While China is Forecast to Grow at 12.8% CAGR

The Lung Adenocarcinoma Treatment market in the U.S. is estimated at US$1.6 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$2.0 Billion by the year 2030 trailing a CAGR of 12.8% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 7.1% and 8.3% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 7.5% CAGR.

Global Lung Adenocarcinoma Treatment Market - Key Trends & Drivers Summarized

What Makes Lung Adenocarcinoma Stand Out in the Oncology Landscape?

Lung adenocarcinoma, a subtype of non-small cell lung cancer (NSCLC), accounts for nearly 40% of all lung cancer cases, making it the most prevalent form of the disease. Its increasing incidence is largely linked to environmental exposures, including air pollution and smoking, as well as genetic predispositions in certain populations. What sets it apart in the oncology spectrum is its complex molecular profile, which has spurred a wave of targeted therapy innovations. From EGFR mutations to ALK and ROS1 rearrangements, the identification of oncogenic drivers has redefined therapeutic strategies, pushing pharmaceutical research toward more personalized, biomarker-driven treatment regimens. In contrast to traditional chemotherapy, these therapies offer higher efficacy with fewer systemic side effects, transforming the patient care paradigm in both early-stage and advanced settings.

Are Emerging Therapies Reshaping the Standard of Care?

The therapeutic landscape for lung adenocarcinoma has undergone a radical shift with the introduction of immunotherapies and next-generation targeted treatments. Immune checkpoint inhibitors such as pembrolizumab and nivolumab have demonstrated significant survival benefits in patients with high PD-L1 expression, especially when used as first-line treatments. Meanwhile, the advent of third-generation tyrosine kinase inhibitors (TKIs) targeting EGFR and other mutations has further improved outcomes, particularly in resistant or metastatic cases. Combination therapies-pairing immune agents with chemotherapeutics or TKIs-are being actively explored and show promise in clinical trials. Additionally, bispecific antibodies, antibody-drug conjugates (ADCs), and mRNA-based approaches are in development, expanding the arsenal against tumor progression and drug resistance. These innovations reflect a growing convergence of immunology and genomics in treatment protocols.

How Are Diagnostic Breakthroughs Fueling Therapeutic Precision?

Diagnostic advancements are playing a pivotal role in optimizing treatment pathways for lung adenocarcinoma. Liquid biopsy, next-generation sequencing (NGS), and multiplex molecular profiling have emerged as indispensable tools in clinical decision-making. These technologies allow for the detection of actionable mutations from minimal biological material, enabling real-time monitoring of disease progression and therapeutic efficacy. Importantly, the integration of AI-driven diagnostic platforms is enhancing the speed and accuracy of pathology analysis, improving turnaround times for treatment initiation. As precision medicine becomes the norm, regulatory bodies worldwide are also aligning with this shift-streamlining the approval process for companion diagnostics and ensuring broader access. These trends not only improve prognosis but also enable the implementation of more adaptive and cost-effective treatment models.

What Is Driving the Growth Momentum in the Lung Adenocarcinoma Treatment Market?

The growth in the lung adenocarcinoma treatment market is driven by several factors rooted in technological innovation, changing clinical practices, and evolving patient demographics. One major driver is the increasing adoption of molecular diagnostics and personalized treatment approaches, which is accelerating drug development and patient stratification. Another is the expansion of indications for immune checkpoint inhibitors and targeted therapies, which has significantly widened the eligible patient pool. Advances in AI and machine learning are streamlining drug discovery and clinical trial design, reducing time-to-market for novel treatments. Additionally, a rising global geriatric population-more susceptible to lung cancers-and increased awareness in emerging economies are boosting early diagnosis and treatment rates. Growing collaborations between pharmaceutical companies, biotech firms, and academic institutions are also facilitating the rapid development of combination therapies and next-generation biologics. Finally, reimbursement support and healthcare policy reforms in key markets are enabling better patient access to premium therapies, further propelling market expansion.

SCOPE OF STUDY:

The report analyzes the Lung Adenocarcinoma Treatment market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Treatment (Chemotherapy, Targeted Therapy, Immunotherapy, Radiation Therapy, Others); End-Use Channel (Hospitals, Specialty Clinics, Others)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 48 Featured) -

  • AbbVie Inc.
  • Amgen Inc.
  • AstraZeneca PLC
  • BeiGene, Ltd.
  • BioNTech SE
  • Biotheus Inc.
  • Boehringer Ingelheim International GmbH
  • Bristol-Myers Squibb Company
  • CStone Pharmaceuticals
  • Daiichi Sankyo Company, Limited
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd
  • Genentech, Inc. (a member of the Roche Group)
  • GlaxoSmithKline plc
  • Johnson & Johnson Services, Inc.
  • Merck & Co., Inc.
  • Novartis AG
  • Pfizer Inc.
  • Sanofi S.A.
  • Takeda Pharmaceutical Company Limited

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • Tariff Impact on Global Supply Chain Patterns
    • Lung Adenocarcinoma Treatment - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Incidence of Lung Adenocarcinoma Globally Spurs Demand for Novel Therapeutic Options
    • Increasing Preference for Targeted Therapies Drives Adoption of Molecularly Guided Treatment Regimens
    • Growing Utilization of Companion Diagnostics Strengthens Business Case for Personalized Medicine
    • Advancements in Liquid Biopsy Technology Expand Addressable Market Opportunity for Early Detection and Monitoring
    • Accelerated FDA Approvals of Novel Oncology Drugs Propel Growth in Precision Treatment Portfolios
    • Increasing Integration of Artificial Intelligence in Oncology Workflows Drives Operational Efficiency and Treatment Accuracy
    • Expansion of Biomarker Testing Infrastructure Generates Demand for Genotype-Driven Therapy Selection
    • Widespread Adoption of Immunotherapy Throws the Spotlight on Checkpoint Inhibitors and Novel Combinations
    • Rise in Awareness and Screening Programs in Emerging Markets Opens New Growth Corridors for Treatment Providers
    • Growing Investments in Oncology R&D Sustain Innovation-Led Growth in Lung Cancer Treatment
    • Increasing Multidisciplinary Approaches in Cancer Care Accelerate Demand for Integrated Treatment Models
    • High Unmet Clinical Need in Refractory and Advanced-Stage Cases Strengthens Market for Next-Generation Therapeutics
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Lung Adenocarcinoma Treatment Market Analysis of Annual Sales in US$ Million for Years 2015 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Lung Adenocarcinoma Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Lung Adenocarcinoma Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 4: World 15-Year Perspective for Lung Adenocarcinoma Treatment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Chemotherapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Chemotherapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 7: World 15-Year Perspective for Chemotherapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Targeted Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Targeted Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 10: World 15-Year Perspective for Targeted Therapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Immunotherapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Immunotherapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 13: World 15-Year Perspective for Immunotherapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Radiation Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Radiation Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 16: World 15-Year Perspective for Radiation Therapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Other Treatments by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Other Treatments by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 19: World 15-Year Perspective for Other Treatments by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Hospitals by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Hospitals by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 22: World 15-Year Perspective for Hospitals by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for Specialty Clinics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 24: World Historic Review for Specialty Clinics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 25: World 15-Year Perspective for Specialty Clinics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 26: World Recent Past, Current & Future Analysis for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 27: World Historic Review for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 28: World 15-Year Perspective for Other End-Uses by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Lung Adenocarcinoma Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 29: USA Recent Past, Current & Future Analysis for Lung Adenocarcinoma Treatment by Treatment - Chemotherapy, Targeted Therapy, Immunotherapy, Radiation Therapy and Other Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 30: USA Historic Review for Lung Adenocarcinoma Treatment by Treatment - Chemotherapy, Targeted Therapy, Immunotherapy, Radiation Therapy and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 31: USA 15-Year Perspective for Lung Adenocarcinoma Treatment by Treatment - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Therapy, Immunotherapy, Radiation Therapy and Other Treatments for the Years 2015, 2025 & 2030
    • TABLE 32: USA Recent Past, Current & Future Analysis for Lung Adenocarcinoma Treatment by End-Use Channel - Hospitals, Specialty Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 33: USA Historic Review for Lung Adenocarcinoma Treatment by End-Use Channel - Hospitals, Specialty Clinics and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 34: USA 15-Year Perspective for Lung Adenocarcinoma Treatment by End-Use Channel - Percentage Breakdown of Value Sales for Hospitals, Specialty Clinics and Other End-Uses for the Years 2015, 2025 & 2030
  • CANADA
    • TABLE 35: Canada Recent Past, Current & Future Analysis for Lung Adenocarcinoma Treatment by Treatment - Chemotherapy, Targeted Therapy, Immunotherapy, Radiation Therapy and Other Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 36: Canada Historic Review for Lung Adenocarcinoma Treatment by Treatment - Chemotherapy, Targeted Therapy, Immunotherapy, Radiation Therapy and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 37: Canada 15-Year Perspective for Lung Adenocarcinoma Treatment by Treatment - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Therapy, Immunotherapy, Radiation Therapy and Other Treatments for the Years 2015, 2025 & 2030
    • TABLE 38: Canada Recent Past, Current & Future Analysis for Lung Adenocarcinoma Treatment by End-Use Channel - Hospitals, Specialty Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 39: Canada Historic Review for Lung Adenocarcinoma Treatment by End-Use Channel - Hospitals, Specialty Clinics and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 40: Canada 15-Year Perspective for Lung Adenocarcinoma Treatment by End-Use Channel - Percentage Breakdown of Value Sales for Hospitals, Specialty Clinics and Other End-Uses for the Years 2015, 2025 & 2030
  • JAPAN
    • Lung Adenocarcinoma Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 41: Japan Recent Past, Current & Future Analysis for Lung Adenocarcinoma Treatment by Treatment - Chemotherapy, Targeted Therapy, Immunotherapy, Radiation Therapy and Other Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 42: Japan Historic Review for Lung Adenocarcinoma Treatment by Treatment - Chemotherapy, Targeted Therapy, Immunotherapy, Radiation Therapy and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 43: Japan 15-Year Perspective for Lung Adenocarcinoma Treatment by Treatment - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Therapy, Immunotherapy, Radiation Therapy and Other Treatments for the Years 2015, 2025 & 2030
    • TABLE 44: Japan Recent Past, Current & Future Analysis for Lung Adenocarcinoma Treatment by End-Use Channel - Hospitals, Specialty Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 45: Japan Historic Review for Lung Adenocarcinoma Treatment by End-Use Channel - Hospitals, Specialty Clinics and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 46: Japan 15-Year Perspective for Lung Adenocarcinoma Treatment by End-Use Channel - Percentage Breakdown of Value Sales for Hospitals, Specialty Clinics and Other End-Uses for the Years 2015, 2025 & 2030
  • CHINA
    • Lung Adenocarcinoma Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 47: China Recent Past, Current & Future Analysis for Lung Adenocarcinoma Treatment by Treatment - Chemotherapy, Targeted Therapy, Immunotherapy, Radiation Therapy and Other Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 48: China Historic Review for Lung Adenocarcinoma Treatment by Treatment - Chemotherapy, Targeted Therapy, Immunotherapy, Radiation Therapy and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 49: China 15-Year Perspective for Lung Adenocarcinoma Treatment by Treatment - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Therapy, Immunotherapy, Radiation Therapy and Other Treatments for the Years 2015, 2025 & 2030
    • TABLE 50: China Recent Past, Current & Future Analysis for Lung Adenocarcinoma Treatment by End-Use Channel - Hospitals, Specialty Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 51: China Historic Review for Lung Adenocarcinoma Treatment by End-Use Channel - Hospitals, Specialty Clinics and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 52: China 15-Year Perspective for Lung Adenocarcinoma Treatment by End-Use Channel - Percentage Breakdown of Value Sales for Hospitals, Specialty Clinics and Other End-Uses for the Years 2015, 2025 & 2030
  • EUROPE
    • Lung Adenocarcinoma Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 53: Europe Recent Past, Current & Future Analysis for Lung Adenocarcinoma Treatment by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 54: Europe Historic Review for Lung Adenocarcinoma Treatment by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 55: Europe 15-Year Perspective for Lung Adenocarcinoma Treatment by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
    • TABLE 56: Europe Recent Past, Current & Future Analysis for Lung Adenocarcinoma Treatment by Treatment - Chemotherapy, Targeted Therapy, Immunotherapy, Radiation Therapy and Other Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 57: Europe Historic Review for Lung Adenocarcinoma Treatment by Treatment - Chemotherapy, Targeted Therapy, Immunotherapy, Radiation Therapy and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 58: Europe 15-Year Perspective for Lung Adenocarcinoma Treatment by Treatment - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Therapy, Immunotherapy, Radiation Therapy and Other Treatments for the Years 2015, 2025 & 2030
    • TABLE 59: Europe Recent Past, Current & Future Analysis for Lung Adenocarcinoma Treatment by End-Use Channel - Hospitals, Specialty Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 60: Europe Historic Review for Lung Adenocarcinoma Treatment by End-Use Channel - Hospitals, Specialty Clinics and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 61: Europe 15-Year Perspective for Lung Adenocarcinoma Treatment by End-Use Channel - Percentage Breakdown of Value Sales for Hospitals, Specialty Clinics and Other End-Uses for the Years 2015, 2025 & 2030
  • FRANCE
    • Lung Adenocarcinoma Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 62: France Recent Past, Current & Future Analysis for Lung Adenocarcinoma Treatment by Treatment - Chemotherapy, Targeted Therapy, Immunotherapy, Radiation Therapy and Other Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 63: France Historic Review for Lung Adenocarcinoma Treatment by Treatment - Chemotherapy, Targeted Therapy, Immunotherapy, Radiation Therapy and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 64: France 15-Year Perspective for Lung Adenocarcinoma Treatment by Treatment - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Therapy, Immunotherapy, Radiation Therapy and Other Treatments for the Years 2015, 2025 & 2030
    • TABLE 65: France Recent Past, Current & Future Analysis for Lung Adenocarcinoma Treatment by End-Use Channel - Hospitals, Specialty Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 66: France Historic Review for Lung Adenocarcinoma Treatment by End-Use Channel - Hospitals, Specialty Clinics and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 67: France 15-Year Perspective for Lung Adenocarcinoma Treatment by End-Use Channel - Percentage Breakdown of Value Sales for Hospitals, Specialty Clinics and Other End-Uses for the Years 2015, 2025 & 2030
  • GERMANY
    • Lung Adenocarcinoma Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 68: Germany Recent Past, Current & Future Analysis for Lung Adenocarcinoma Treatment by Treatment - Chemotherapy, Targeted Therapy, Immunotherapy, Radiation Therapy and Other Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 69: Germany Historic Review for Lung Adenocarcinoma Treatment by Treatment - Chemotherapy, Targeted Therapy, Immunotherapy, Radiation Therapy and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 70: Germany 15-Year Perspective for Lung Adenocarcinoma Treatment by Treatment - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Therapy, Immunotherapy, Radiation Therapy and Other Treatments for the Years 2015, 2025 & 2030
    • TABLE 71: Germany Recent Past, Current & Future Analysis for Lung Adenocarcinoma Treatment by End-Use Channel - Hospitals, Specialty Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 72: Germany Historic Review for Lung Adenocarcinoma Treatment by End-Use Channel - Hospitals, Specialty Clinics and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 73: Germany 15-Year Perspective for Lung Adenocarcinoma Treatment by End-Use Channel - Percentage Breakdown of Value Sales for Hospitals, Specialty Clinics and Other End-Uses for the Years 2015, 2025 & 2030
  • ITALY
    • TABLE 74: Italy Recent Past, Current & Future Analysis for Lung Adenocarcinoma Treatment by Treatment - Chemotherapy, Targeted Therapy, Immunotherapy, Radiation Therapy and Other Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 75: Italy Historic Review for Lung Adenocarcinoma Treatment by Treatment - Chemotherapy, Targeted Therapy, Immunotherapy, Radiation Therapy and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 76: Italy 15-Year Perspective for Lung Adenocarcinoma Treatment by Treatment - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Therapy, Immunotherapy, Radiation Therapy and Other Treatments for the Years 2015, 2025 & 2030
    • TABLE 77: Italy Recent Past, Current & Future Analysis for Lung Adenocarcinoma Treatment by End-Use Channel - Hospitals, Specialty Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 78: Italy Historic Review for Lung Adenocarcinoma Treatment by End-Use Channel - Hospitals, Specialty Clinics and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 79: Italy 15-Year Perspective for Lung Adenocarcinoma Treatment by End-Use Channel - Percentage Breakdown of Value Sales for Hospitals, Specialty Clinics and Other End-Uses for the Years 2015, 2025 & 2030
  • UNITED KINGDOM
    • Lung Adenocarcinoma Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 80: UK Recent Past, Current & Future Analysis for Lung Adenocarcinoma Treatment by Treatment - Chemotherapy, Targeted Therapy, Immunotherapy, Radiation Therapy and Other Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 81: UK Historic Review for Lung Adenocarcinoma Treatment by Treatment - Chemotherapy, Targeted Therapy, Immunotherapy, Radiation Therapy and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 82: UK 15-Year Perspective for Lung Adenocarcinoma Treatment by Treatment - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Therapy, Immunotherapy, Radiation Therapy and Other Treatments for the Years 2015, 2025 & 2030
    • TABLE 83: UK Recent Past, Current & Future Analysis for Lung Adenocarcinoma Treatment by End-Use Channel - Hospitals, Specialty Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 84: UK Historic Review for Lung Adenocarcinoma Treatment by End-Use Channel - Hospitals, Specialty Clinics and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 85: UK 15-Year Perspective for Lung Adenocarcinoma Treatment by End-Use Channel - Percentage Breakdown of Value Sales for Hospitals, Specialty Clinics and Other End-Uses for the Years 2015, 2025 & 2030
  • SPAIN
    • TABLE 86: Spain Recent Past, Current & Future Analysis for Lung Adenocarcinoma Treatment by Treatment - Chemotherapy, Targeted Therapy, Immunotherapy, Radiation Therapy and Other Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 87: Spain Historic Review for Lung Adenocarcinoma Treatment by Treatment - Chemotherapy, Targeted Therapy, Immunotherapy, Radiation Therapy and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 88: Spain 15-Year Perspective for Lung Adenocarcinoma Treatment by Treatment - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Therapy, Immunotherapy, Radiation Therapy and Other Treatments for the Years 2015, 2025 & 2030
    • TABLE 89: Spain Recent Past, Current & Future Analysis for Lung Adenocarcinoma Treatment by End-Use Channel - Hospitals, Specialty Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 90: Spain Historic Review for Lung Adenocarcinoma Treatment by End-Use Channel - Hospitals, Specialty Clinics and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 91: Spain 15-Year Perspective for Lung Adenocarcinoma Treatment by End-Use Channel - Percentage Breakdown of Value Sales for Hospitals, Specialty Clinics and Other End-Uses for the Years 2015, 2025 & 2030
  • RUSSIA
    • TABLE 92: Russia Recent Past, Current & Future Analysis for Lung Adenocarcinoma Treatment by Treatment - Chemotherapy, Targeted Therapy, Immunotherapy, Radiation Therapy and Other Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Russia Historic Review for Lung Adenocarcinoma Treatment by Treatment - Chemotherapy, Targeted Therapy, Immunotherapy, Radiation Therapy and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 94: Russia 15-Year Perspective for Lung Adenocarcinoma Treatment by Treatment - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Therapy, Immunotherapy, Radiation Therapy and Other Treatments for the Years 2015, 2025 & 2030
    • TABLE 95: Russia Recent Past, Current & Future Analysis for Lung Adenocarcinoma Treatment by End-Use Channel - Hospitals, Specialty Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 96: Russia Historic Review for Lung Adenocarcinoma Treatment by End-Use Channel - Hospitals, Specialty Clinics and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 97: Russia 15-Year Perspective for Lung Adenocarcinoma Treatment by End-Use Channel - Percentage Breakdown of Value Sales for Hospitals, Specialty Clinics and Other End-Uses for the Years 2015, 2025 & 2030
  • REST OF EUROPE
    • TABLE 98: Rest of Europe Recent Past, Current & Future Analysis for Lung Adenocarcinoma Treatment by Treatment - Chemotherapy, Targeted Therapy, Immunotherapy, Radiation Therapy and Other Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Rest of Europe Historic Review for Lung Adenocarcinoma Treatment by Treatment - Chemotherapy, Targeted Therapy, Immunotherapy, Radiation Therapy and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 100: Rest of Europe 15-Year Perspective for Lung Adenocarcinoma Treatment by Treatment - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Therapy, Immunotherapy, Radiation Therapy and Other Treatments for the Years 2015, 2025 & 2030
    • TABLE 101: Rest of Europe Recent Past, Current & Future Analysis for Lung Adenocarcinoma Treatment by End-Use Channel - Hospitals, Specialty Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 102: Rest of Europe Historic Review for Lung Adenocarcinoma Treatment by End-Use Channel - Hospitals, Specialty Clinics and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 103: Rest of Europe 15-Year Perspective for Lung Adenocarcinoma Treatment by End-Use Channel - Percentage Breakdown of Value Sales for Hospitals, Specialty Clinics and Other End-Uses for the Years 2015, 2025 & 2030
  • ASIA-PACIFIC
    • Lung Adenocarcinoma Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 104: Asia-Pacific Recent Past, Current & Future Analysis for Lung Adenocarcinoma Treatment by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 105: Asia-Pacific Historic Review for Lung Adenocarcinoma Treatment by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 106: Asia-Pacific 15-Year Perspective for Lung Adenocarcinoma Treatment by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
    • TABLE 107: Asia-Pacific Recent Past, Current & Future Analysis for Lung Adenocarcinoma Treatment by Treatment - Chemotherapy, Targeted Therapy, Immunotherapy, Radiation Therapy and Other Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 108: Asia-Pacific Historic Review for Lung Adenocarcinoma Treatment by Treatment - Chemotherapy, Targeted Therapy, Immunotherapy, Radiation Therapy and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 109: Asia-Pacific 15-Year Perspective for Lung Adenocarcinoma Treatment by Treatment - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Therapy, Immunotherapy, Radiation Therapy and Other Treatments for the Years 2015, 2025 & 2030
    • TABLE 110: Asia-Pacific Recent Past, Current & Future Analysis for Lung Adenocarcinoma Treatment by End-Use Channel - Hospitals, Specialty Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 111: Asia-Pacific Historic Review for Lung Adenocarcinoma Treatment by End-Use Channel - Hospitals, Specialty Clinics and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 112: Asia-Pacific 15-Year Perspective for Lung Adenocarcinoma Treatment by End-Use Channel - Percentage Breakdown of Value Sales for Hospitals, Specialty Clinics and Other End-Uses for the Years 2015, 2025 & 2030
  • AUSTRALIA
    • Lung Adenocarcinoma Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 113: Australia Recent Past, Current & Future Analysis for Lung Adenocarcinoma Treatment by Treatment - Chemotherapy, Targeted Therapy, Immunotherapy, Radiation Therapy and Other Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 114: Australia Historic Review for Lung Adenocarcinoma Treatment by Treatment - Chemotherapy, Targeted Therapy, Immunotherapy, Radiation Therapy and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 115: Australia 15-Year Perspective for Lung Adenocarcinoma Treatment by Treatment - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Therapy, Immunotherapy, Radiation Therapy and Other Treatments for the Years 2015, 2025 & 2030
    • TABLE 116: Australia Recent Past, Current & Future Analysis for Lung Adenocarcinoma Treatment by End-Use Channel - Hospitals, Specialty Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 117: Australia Historic Review for Lung Adenocarcinoma Treatment by End-Use Channel - Hospitals, Specialty Clinics and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 118: Australia 15-Year Perspective for Lung Adenocarcinoma Treatment by End-Use Channel - Percentage Breakdown of Value Sales for Hospitals, Specialty Clinics and Other End-Uses for the Years 2015, 2025 & 2030
  • INDIA
    • Lung Adenocarcinoma Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 119: India Recent Past, Current & Future Analysis for Lung Adenocarcinoma Treatment by Treatment - Chemotherapy, Targeted Therapy, Immunotherapy, Radiation Therapy and Other Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 120: India Historic Review for Lung Adenocarcinoma Treatment by Treatment - Chemotherapy, Targeted Therapy, Immunotherapy, Radiation Therapy and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 121: India 15-Year Perspective for Lung Adenocarcinoma Treatment by Treatment - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Therapy, Immunotherapy, Radiation Therapy and Other Treatments for the Years 2015, 2025 & 2030
    • TABLE 122: India Recent Past, Current & Future Analysis for Lung Adenocarcinoma Treatment by End-Use Channel - Hospitals, Specialty Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 123: India Historic Review for Lung Adenocarcinoma Treatment by End-Use Channel - Hospitals, Specialty Clinics and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 124: India 15-Year Perspective for Lung Adenocarcinoma Treatment by End-Use Channel - Percentage Breakdown of Value Sales for Hospitals, Specialty Clinics and Other End-Uses for the Years 2015, 2025 & 2030
  • SOUTH KOREA
    • TABLE 125: South Korea Recent Past, Current & Future Analysis for Lung Adenocarcinoma Treatment by Treatment - Chemotherapy, Targeted Therapy, Immunotherapy, Radiation Therapy and Other Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 126: South Korea Historic Review for Lung Adenocarcinoma Treatment by Treatment - Chemotherapy, Targeted Therapy, Immunotherapy, Radiation Therapy and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 127: South Korea 15-Year Perspective for Lung Adenocarcinoma Treatment by Treatment - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Therapy, Immunotherapy, Radiation Therapy and Other Treatments for the Years 2015, 2025 & 2030
    • TABLE 128: South Korea Recent Past, Current & Future Analysis for Lung Adenocarcinoma Treatment by End-Use Channel - Hospitals, Specialty Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 129: South Korea Historic Review for Lung Adenocarcinoma Treatment by End-Use Channel - Hospitals, Specialty Clinics and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 130: South Korea 15-Year Perspective for Lung Adenocarcinoma Treatment by End-Use Channel - Percentage Breakdown of Value Sales for Hospitals, Specialty Clinics and Other End-Uses for the Years 2015, 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 131: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Lung Adenocarcinoma Treatment by Treatment - Chemotherapy, Targeted Therapy, Immunotherapy, Radiation Therapy and Other Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 132: Rest of Asia-Pacific Historic Review for Lung Adenocarcinoma Treatment by Treatment - Chemotherapy, Targeted Therapy, Immunotherapy, Radiation Therapy and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 133: Rest of Asia-Pacific 15-Year Perspective for Lung Adenocarcinoma Treatment by Treatment - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Therapy, Immunotherapy, Radiation Therapy and Other Treatments for the Years 2015, 2025 & 2030
    • TABLE 134: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Lung Adenocarcinoma Treatment by End-Use Channel - Hospitals, Specialty Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 135: Rest of Asia-Pacific Historic Review for Lung Adenocarcinoma Treatment by End-Use Channel - Hospitals, Specialty Clinics and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 136: Rest of Asia-Pacific 15-Year Perspective for Lung Adenocarcinoma Treatment by End-Use Channel - Percentage Breakdown of Value Sales for Hospitals, Specialty Clinics and Other End-Uses for the Years 2015, 2025 & 2030
  • LATIN AMERICA
    • Lung Adenocarcinoma Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 137: Latin America Recent Past, Current & Future Analysis for Lung Adenocarcinoma Treatment by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 138: Latin America Historic Review for Lung Adenocarcinoma Treatment by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 139: Latin America 15-Year Perspective for Lung Adenocarcinoma Treatment by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030
    • TABLE 140: Latin America Recent Past, Current & Future Analysis for Lung Adenocarcinoma Treatment by Treatment - Chemotherapy, Targeted Therapy, Immunotherapy, Radiation Therapy and Other Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 141: Latin America Historic Review for Lung Adenocarcinoma Treatment by Treatment - Chemotherapy, Targeted Therapy, Immunotherapy, Radiation Therapy and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 142: Latin America 15-Year Perspective for Lung Adenocarcinoma Treatment by Treatment - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Therapy, Immunotherapy, Radiation Therapy and Other Treatments for the Years 2015, 2025 & 2030
    • TABLE 143: Latin America Recent Past, Current & Future Analysis for Lung Adenocarcinoma Treatment by End-Use Channel - Hospitals, Specialty Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 144: Latin America Historic Review for Lung Adenocarcinoma Treatment by End-Use Channel - Hospitals, Specialty Clinics and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 145: Latin America 15-Year Perspective for Lung Adenocarcinoma Treatment by End-Use Channel - Percentage Breakdown of Value Sales for Hospitals, Specialty Clinics and Other End-Uses for the Years 2015, 2025 & 2030
  • ARGENTINA
    • TABLE 146: Argentina Recent Past, Current & Future Analysis for Lung Adenocarcinoma Treatment by Treatment - Chemotherapy, Targeted Therapy, Immunotherapy, Radiation Therapy and Other Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 147: Argentina Historic Review for Lung Adenocarcinoma Treatment by Treatment - Chemotherapy, Targeted Therapy, Immunotherapy, Radiation Therapy and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 148: Argentina 15-Year Perspective for Lung Adenocarcinoma Treatment by Treatment - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Therapy, Immunotherapy, Radiation Therapy and Other Treatments for the Years 2015, 2025 & 2030
    • TABLE 149: Argentina Recent Past, Current & Future Analysis for Lung Adenocarcinoma Treatment by End-Use Channel - Hospitals, Specialty Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 150: Argentina Historic Review for Lung Adenocarcinoma Treatment by End-Use Channel - Hospitals, Specialty Clinics and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 151: Argentina 15-Year Perspective for Lung Adenocarcinoma Treatment by End-Use Channel - Percentage Breakdown of Value Sales for Hospitals, Specialty Clinics and Other End-Uses for the Years 2015, 2025 & 2030
  • BRAZIL
    • TABLE 152: Brazil Recent Past, Current & Future Analysis for Lung Adenocarcinoma Treatment by Treatment - Chemotherapy, Targeted Therapy, Immunotherapy, Radiation Therapy and Other Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 153: Brazil Historic Review for Lung Adenocarcinoma Treatment by Treatment - Chemotherapy, Targeted Therapy, Immunotherapy, Radiation Therapy and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 154: Brazil 15-Year Perspective for Lung Adenocarcinoma Treatment by Treatment - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Therapy, Immunotherapy, Radiation Therapy and Other Treatments for the Years 2015, 2025 & 2030
    • TABLE 155: Brazil Recent Past, Current & Future Analysis for Lung Adenocarcinoma Treatment by End-Use Channel - Hospitals, Specialty Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 156: Brazil Historic Review for Lung Adenocarcinoma Treatment by End-Use Channel - Hospitals, Specialty Clinics and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 157: Brazil 15-Year Perspective for Lung Adenocarcinoma Treatment by End-Use Channel - Percentage Breakdown of Value Sales for Hospitals, Specialty Clinics and Other End-Uses for the Years 2015, 2025 & 2030
  • MEXICO
    • TABLE 158: Mexico Recent Past, Current & Future Analysis for Lung Adenocarcinoma Treatment by Treatment - Chemotherapy, Targeted Therapy, Immunotherapy, Radiation Therapy and Other Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 159: Mexico Historic Review for Lung Adenocarcinoma Treatment by Treatment - Chemotherapy, Targeted Therapy, Immunotherapy, Radiation Therapy and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 160: Mexico 15-Year Perspective for Lung Adenocarcinoma Treatment by Treatment - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Therapy, Immunotherapy, Radiation Therapy and Other Treatments for the Years 2015, 2025 & 2030
    • TABLE 161: Mexico Recent Past, Current & Future Analysis for Lung Adenocarcinoma Treatment by End-Use Channel - Hospitals, Specialty Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 162: Mexico Historic Review for Lung Adenocarcinoma Treatment by End-Use Channel - Hospitals, Specialty Clinics and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 163: Mexico 15-Year Perspective for Lung Adenocarcinoma Treatment by End-Use Channel - Percentage Breakdown of Value Sales for Hospitals, Specialty Clinics and Other End-Uses for the Years 2015, 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 164: Rest of Latin America Recent Past, Current & Future Analysis for Lung Adenocarcinoma Treatment by Treatment - Chemotherapy, Targeted Therapy, Immunotherapy, Radiation Therapy and Other Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 165: Rest of Latin America Historic Review for Lung Adenocarcinoma Treatment by Treatment - Chemotherapy, Targeted Therapy, Immunotherapy, Radiation Therapy and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 166: Rest of Latin America 15-Year Perspective for Lung Adenocarcinoma Treatment by Treatment - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Therapy, Immunotherapy, Radiation Therapy and Other Treatments for the Years 2015, 2025 & 2030
    • TABLE 167: Rest of Latin America Recent Past, Current & Future Analysis for Lung Adenocarcinoma Treatment by End-Use Channel - Hospitals, Specialty Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 168: Rest of Latin America Historic Review for Lung Adenocarcinoma Treatment by End-Use Channel - Hospitals, Specialty Clinics and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 169: Rest of Latin America 15-Year Perspective for Lung Adenocarcinoma Treatment by End-Use Channel - Percentage Breakdown of Value Sales for Hospitals, Specialty Clinics and Other End-Uses for the Years 2015, 2025 & 2030
  • MIDDLE EAST
    • Lung Adenocarcinoma Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 170: Middle East Recent Past, Current & Future Analysis for Lung Adenocarcinoma Treatment by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 171: Middle East Historic Review for Lung Adenocarcinoma Treatment by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 172: Middle East 15-Year Perspective for Lung Adenocarcinoma Treatment by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030
    • TABLE 173: Middle East Recent Past, Current & Future Analysis for Lung Adenocarcinoma Treatment by Treatment - Chemotherapy, Targeted Therapy, Immunotherapy, Radiation Therapy and Other Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 174: Middle East Historic Review for Lung Adenocarcinoma Treatment by Treatment - Chemotherapy, Targeted Therapy, Immunotherapy, Radiation Therapy and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 175: Middle East 15-Year Perspective for Lung Adenocarcinoma Treatment by Treatment - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Therapy, Immunotherapy, Radiation Therapy and Other Treatments for the Years 2015, 2025 & 2030
    • TABLE 176: Middle East Recent Past, Current & Future Analysis for Lung Adenocarcinoma Treatment by End-Use Channel - Hospitals, Specialty Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 177: Middle East Historic Review for Lung Adenocarcinoma Treatment by End-Use Channel - Hospitals, Specialty Clinics and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 178: Middle East 15-Year Perspective for Lung Adenocarcinoma Treatment by End-Use Channel - Percentage Breakdown of Value Sales for Hospitals, Specialty Clinics and Other End-Uses for the Years 2015, 2025 & 2030
  • IRAN
    • TABLE 179: Iran Recent Past, Current & Future Analysis for Lung Adenocarcinoma Treatment by Treatment - Chemotherapy, Targeted Therapy, Immunotherapy, Radiation Therapy and Other Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 180: Iran Historic Review for Lung Adenocarcinoma Treatment by Treatment - Chemotherapy, Targeted Therapy, Immunotherapy, Radiation Therapy and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 181: Iran 15-Year Perspective for Lung Adenocarcinoma Treatment by Treatment - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Therapy, Immunotherapy, Radiation Therapy and Other Treatments for the Years 2015, 2025 & 2030
    • TABLE 182: Iran Recent Past, Current & Future Analysis for Lung Adenocarcinoma Treatment by End-Use Channel - Hospitals, Specialty Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 183: Iran Historic Review for Lung Adenocarcinoma Treatment by End-Use Channel - Hospitals, Specialty Clinics and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 184: Iran 15-Year Perspective for Lung Adenocarcinoma Treatment by End-Use Channel - Percentage Breakdown of Value Sales for Hospitals, Specialty Clinics and Other End-Uses for the Years 2015, 2025 & 2030
  • ISRAEL
    • TABLE 185: Israel Recent Past, Current & Future Analysis for Lung Adenocarcinoma Treatment by Treatment - Chemotherapy, Targeted Therapy, Immunotherapy, Radiation Therapy and Other Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 186: Israel Historic Review for Lung Adenocarcinoma Treatment by Treatment - Chemotherapy, Targeted Therapy, Immunotherapy, Radiation Therapy and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 187: Israel 15-Year Perspective for Lung Adenocarcinoma Treatment by Treatment - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Therapy, Immunotherapy, Radiation Therapy and Other Treatments for the Years 2015, 2025 & 2030
    • TABLE 188: Israel Recent Past, Current & Future Analysis for Lung Adenocarcinoma Treatment by End-Use Channel - Hospitals, Specialty Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 189: Israel Historic Review for Lung Adenocarcinoma Treatment by End-Use Channel - Hospitals, Specialty Clinics and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 190: Israel 15-Year Perspective for Lung Adenocarcinoma Treatment by End-Use Channel - Percentage Breakdown of Value Sales for Hospitals, Specialty Clinics and Other End-Uses for the Years 2015, 2025 & 2030
  • SAUDI ARABIA
    • TABLE 191: Saudi Arabia Recent Past, Current & Future Analysis for Lung Adenocarcinoma Treatment by Treatment - Chemotherapy, Targeted Therapy, Immunotherapy, Radiation Therapy and Other Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 192: Saudi Arabia Historic Review for Lung Adenocarcinoma Treatment by Treatment - Chemotherapy, Targeted Therapy, Immunotherapy, Radiation Therapy and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 193: Saudi Arabia 15-Year Perspective for Lung Adenocarcinoma Treatment by Treatment - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Therapy, Immunotherapy, Radiation Therapy and Other Treatments for the Years 2015, 2025 & 2030
    • TABLE 194: Saudi Arabia Recent Past, Current & Future Analysis for Lung Adenocarcinoma Treatment by End-Use Channel - Hospitals, Specialty Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 195: Saudi Arabia Historic Review for Lung Adenocarcinoma Treatment by End-Use Channel - Hospitals, Specialty Clinics and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 196: Saudi Arabia 15-Year Perspective for Lung Adenocarcinoma Treatment by End-Use Channel - Percentage Breakdown of Value Sales for Hospitals, Specialty Clinics and Other End-Uses for the Years 2015, 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 197: UAE Recent Past, Current & Future Analysis for Lung Adenocarcinoma Treatment by Treatment - Chemotherapy, Targeted Therapy, Immunotherapy, Radiation Therapy and Other Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 198: UAE Historic Review for Lung Adenocarcinoma Treatment by Treatment - Chemotherapy, Targeted Therapy, Immunotherapy, Radiation Therapy and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 199: UAE 15-Year Perspective for Lung Adenocarcinoma Treatment by Treatment - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Therapy, Immunotherapy, Radiation Therapy and Other Treatments for the Years 2015, 2025 & 2030
    • TABLE 200: UAE Recent Past, Current & Future Analysis for Lung Adenocarcinoma Treatment by End-Use Channel - Hospitals, Specialty Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 201: UAE Historic Review for Lung Adenocarcinoma Treatment by End-Use Channel - Hospitals, Specialty Clinics and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 202: UAE 15-Year Perspective for Lung Adenocarcinoma Treatment by End-Use Channel - Percentage Breakdown of Value Sales for Hospitals, Specialty Clinics and Other End-Uses for the Years 2015, 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 203: Rest of Middle East Recent Past, Current & Future Analysis for Lung Adenocarcinoma Treatment by Treatment - Chemotherapy, Targeted Therapy, Immunotherapy, Radiation Therapy and Other Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 204: Rest of Middle East Historic Review for Lung Adenocarcinoma Treatment by Treatment - Chemotherapy, Targeted Therapy, Immunotherapy, Radiation Therapy and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 205: Rest of Middle East 15-Year Perspective for Lung Adenocarcinoma Treatment by Treatment - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Therapy, Immunotherapy, Radiation Therapy and Other Treatments for the Years 2015, 2025 & 2030
    • TABLE 206: Rest of Middle East Recent Past, Current & Future Analysis for Lung Adenocarcinoma Treatment by End-Use Channel - Hospitals, Specialty Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 207: Rest of Middle East Historic Review for Lung Adenocarcinoma Treatment by End-Use Channel - Hospitals, Specialty Clinics and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 208: Rest of Middle East 15-Year Perspective for Lung Adenocarcinoma Treatment by End-Use Channel - Percentage Breakdown of Value Sales for Hospitals, Specialty Clinics and Other End-Uses for the Years 2015, 2025 & 2030
  • AFRICA
    • Lung Adenocarcinoma Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 209: Africa Recent Past, Current & Future Analysis for Lung Adenocarcinoma Treatment by Treatment - Chemotherapy, Targeted Therapy, Immunotherapy, Radiation Therapy and Other Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 210: Africa Historic Review for Lung Adenocarcinoma Treatment by Treatment - Chemotherapy, Targeted Therapy, Immunotherapy, Radiation Therapy and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 211: Africa 15-Year Perspective for Lung Adenocarcinoma Treatment by Treatment - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Therapy, Immunotherapy, Radiation Therapy and Other Treatments for the Years 2015, 2025 & 2030
    • TABLE 212: Africa Recent Past, Current & Future Analysis for Lung Adenocarcinoma Treatment by End-Use Channel - Hospitals, Specialty Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 213: Africa Historic Review for Lung Adenocarcinoma Treatment by End-Use Channel - Hospitals, Specialty Clinics and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 214: Africa 15-Year Perspective for Lung Adenocarcinoma Treatment by End-Use Channel - Percentage Breakdown of Value Sales for Hospitals, Specialty Clinics and Other End-Uses for the Years 2015, 2025 & 2030

IV. COMPETITION